A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Communications Biology Année : 2021

A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity

Résumé

During the cancerous transformation of normal hepatocytes into hepatocellular carcinoma (HCC), the enzyme catalyzing the first rate-limiting step of glycolysis, namely the glucokinase (GCK), is replaced by the higher affinity isoenzyme, hexokinase 2 (HK2). Here, we show that in HCC tumors the highest expression level of HK2 is inversely correlated to GCK expression, and is associated to poor prognosis for patient survival. To further explore functional consequences of the GCK-to-HK2 isoenzyme switch occurring during carcinogenesis, HK2 was knocked-out in the HCC cell line Huh7 and replaced by GCK, to generate the Huh7-GCK+/HK2? cell line. HK2 knockdown and GCK expression rewired central carbon metabolism, stimulated mitochondrial respiration and restored essential metabolic functions of normal hepatocytes such as lipogenesis, VLDL secretion, glycogen storage. It also reactivated innate immune responses and sensitivity to natural killer cells, showing that consequences of the HK switch extend beyond metabolic reprogramming.
Fichier principal
Vignette du fichier
MRGM_CB_2021_Perrin-Cocon.pdf (2.57 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03403454 , version 1 (26-10-2021)

Licence

Paternité

Identifiants

Citer

Laure Perrin-Cocon, Pierre-Olivier Vidalain, Clemence Jacquemin, Anne Aublin-Gex, Keedrian Olmstead, et al.. A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity. Communications Biology, 2021, 4, pp.217. ⟨10.1038/s42003-021-01749-3⟩. ⟨hal-03403454⟩
173 Consultations
123 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More